X

Health & Biotech

AdAlta and SYNthesis BioVentures collaborate on advanced cell-based cancer immunotherapy

AdAlta and SYNthesis BioVentures Fund (SYNBV) are collaborating to form AdCella, a jointly owned entity aimed at facilitating the entry…

ScoPo’s (actually Wilkie’s) Powerplays: Blinklab soars 32.5% in first healthcare IPO of 2024

Blinklab (ASX:BB1) has became the first healthcare IPO so far of 2024 listing on April 4 with an impressive 32.5%…

Online sales of Calmer Co wellness products surpasses 10k per day for March

Health and wellness company The Calmer Co has reported a 25% increase in monthly online sales compared to February, with…

‘Overnight success story 18 years in the making’ – Imricor to transform cardiac ablation market

Imricor is at the forefront in advancing MRI-compatible products for US$8 billion cardiac catheter ablation market.

ASX Health Winners March: A rebound? Aussie biotech sector is on the radar of Asian investors

There are signs the healthcare space is coming back to life after a hard 2023. Six ASX healthcare companies fronted…

ASX Health Stocks: Acrux jumps 70pc after launching its acne gel in the US

Acrux announced launch of acne gel in the US. Recce Pharma granted Israeli patent for its anti-infectives R327 and R529.

Anteris Technologies is leading a heart condition treatment revolution

Anteris Technologies (ASX:AVR) has developed the world’s first, single piece transcatheter aortic valve called the DurAVR THV.

Medtech Optiscan beefs up operations in US, hires two high-level execs

Optiscan is beefing up its presence in the US as it works toward securing US regulatory approvals for its confocal…

ASX Health Stocks: NSB jumps 30pc after disclosing upcoming meeting with US FDA

Neuroscientific Biopharma to have a pre-IND meeting with US FDA. The NSB stock price jumped as high as 30pc this…

Melodiol’s Mernova gains more traction in Canada: revenues increase, new products launched

Melodiol Global Health Limited (ASX:ME1)’s wholly-owned Canadian subsidiary, Mernova, has continued its gain traction on the back of strong demand…